The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns and outcomes with HER2-directed therapy for the treatment of HER2-positive metastatic breast cancer.
Rakesh Luthra
No relevant relationships to disclose
Maxine Fisher
No relevant relationships to disclose
Melissa Brammer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche